Investigating a new target for cancer treatment
Official title: Targeting a Novel Pocket on ITGAV
Funded at University of California, San Diego · NIH-10930939 · Data updated 2026-11-12
This study is exploring new ways to treat leukemia and solid tumors by looking at a protein called Integrin Alpha V, using both computer models and lab tests, to find better treatment options for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 29, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $90,947 |
| NIH project number | 5K00CA274649-04 |
| Project ID | NIH-10930939 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute leukemias or advanced solid tumors who are seeking new treatment options.
✕Less likely to help
Patients with non-cancerous conditions or those whose cancers do not involve the targeted pathways may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for various types of leukemia and solid tumors by targeting a specific protein called Integrin Alpha V (ITGAV). The approach combines advanced mathematical modeling with laboratory experiments to identify effective treatment strategies. Researchers will utilize CRISPR technology to screen and validate the role of ITGAV in cancer cell survival, aiming to uncover new therapeutic options for patients. The project seeks to enhance our understanding of cancer complexities and improve treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with leukemia and solid tumors.
How similar studies have gone: Previous research has shown promise in targeting integrins for cancer treatment, indicating that this approach may lead to significant advancements in therapy.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Mattson, Nicole — University of California, San Diego
- Study coordinator: Mattson, Nicole
Related research
Other NIH-funded projects on the same topics.
-
Improved MRI guidance for pediatric heart catheterization using autonomous multi-beat image synthesis
Aiming to make MRI-guided pediatric heart catheterizations safer and more reliable by using smart, multi-beat data fusion to produce clearer real-time MRI images.
-
Adapting a combination approach to reduce heavy drinking and boost HIV care and prevention among young men
A pilot project tests a proven program that helps young men cut down on heavy drinking and improves HIV treatment and prevention outcomes.
-
How specific anti-NMDAR1 antibodies in the blood may affect memory and brain protection
This research is exploring whether natural or abnormal anti-NMDAR1 antibodies in the blood influence memory, behavior, and brain protection in humans.
-
Screening and treatment of Chlamydia infection in pregnancy to help prevent preterm birth
This grant studies whether screening pregnant people for Chlamydia trachomatis and treating those who are positive can reduce the risk of preterm birth.
-
Pharmacometrics Core at UC San Diego
A pharmacometrics core is funded to support researchers in analyzing drug data to improve how medicines work for patients.
-
Milk Analytics Core for Precision Dairy Research
A core facility at UC San Diego will provide specialized milk analysis services to support research on dairy biology and human health.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.